{
    "clinical_study": {
        "@rank": "161450", 
        "arm_group": {
            "arm_group_label": "Imitrex and Treximet", 
            "description": "Imitrex 100mg as needed Treximet 85/500mg"
        }, 
        "brief_summary": {
            "textblock": "The primary objective is to determine whether inflammatory markers, such as C-Reactive\n      Protein (CRP), Calcitonin Gene-Related Peptide (CGRP), Vasoactive Intestinal Polypeptide\n      (VIP), or Substance P (SP) are reduced in patients having a migraine headache when treated\n      with Imitrex or Treximet.\n\n      The secondary objective is to determine the effects of Imitrex and Treximet on C-Reactive\n      Protein (CRP) in patients with active migraine headaches."
        }, 
        "brief_title": "Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache", 
        "completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Migraine is a neurovascular process involving the brain and related structures.\n      Neuroinflammatory substances such as CRP, CGRP, VIP, SP, and prostaglandins are liberated\n      during the migraine.  Elevation of these markers may be associated with other conditions\n      which contain an inflammatory component such as coronary artery disease.  VIP is an\n      inflammation and pain transmission, and thus are markers of sensory nociceptive neurons.\n\n      During this study, the subjects will have the following inflammation markers analyzed:\n      C-Reactive Protein (CRP), Calcitonin Gene-Related Peptide (CGRP), Vasoactive Intestinal\n      Polypeptide (VIP), and Substance P (SP)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must sign an informed consent\n\n          -  Males and females 18 - 65 years of age\n\n          -  Have episodic migraine headaches\n\n          -  Patients to satisfy the diagnosis of migraine headaches with aura, without aura or\n             mixed\n\n          -  Must be able to differentiate migraine headaches from other headaches\n\n          -  Diagnosis of migraines for at least 6 months\n\n        Exclusion Criteria:\n\n          -  Any medical condition, in the opinion of the investigator, that would make the\n             subject unsuitable for enrollment\n\n          -  Basilar or hemiplegic migraine headaches\n\n          -  Pregnant woman or a nursing mother\n\n          -  History (within 1 year) or current evidence of grug or alcohol abuse\n\n          -  More than 15 migraine headaches per month\n\n          -  Chronic daily headache\n\n          -  Chronic use of NonSteroidalAntiInglammatoryDrugs\n\n          -  Current participation in a research study or within the last 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Male and female patients with migraine headaches."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916395", 
            "org_study_id": "GR10"
        }, 
        "intervention": {
            "arm_group_label": "Imitrex and Treximet", 
            "description": "sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.", 
            "intervention_name": "sumatriptan and Treximet", 
            "intervention_type": "Drug", 
            "other_name": [
                "Imitrex 100mg", 
                "Treximet 85/500mg"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sumatriptan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Migraine", 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49009"
                }, 
                "name": "Westside Family Medical Center, PC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Comparison of Treximet and Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache.", 
        "overall_official": {
            "affiliation": "Family Practice", 
            "last_name": "Gary E Ruoff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The outcome will be to determine whether inflammatory markers are reduced in patients having a migraine when treated with Imitrex 100mg or Treximet.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916395"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Westside Family Medical Center, P.C.", 
            "investigator_full_name": "Gary E. Ruoff, M.D.", 
            "investigator_title": "Director of Clinical Research", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Westside Family Medical Center, P.C.", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Gary E. Ruoff, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Observational Model: Case-Crossover, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2009"
    }
}